Trader Edge
Publicado em 10/03/2026 às 11:10
Vertex Pharmaceuticals (VRTX) Stock Surges 5% Following Positive Kidney Disease Trial Results - Blockonomi
Shares of Vertex climbed approximately 5-7% following successful phase 3 trial results for povetacicept in treating IgA nephropathy.
• Trial participants experienced a 52% decrease in urine protein le... [3056 symbols]
PUBLICIDADE